1. Home
  2. NRGV vs TBPH Comparison

NRGV vs TBPH Comparison

Compare NRGV & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Energy Vault Holdings Inc.

NRGV

Energy Vault Holdings Inc.

HOLD

Current Price

$3.05

Market Cap

912.8M

Sector

Miscellaneous

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$13.50

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRGV
TBPH
Founded
2017
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
912.8M
1.0B
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
NRGV
TBPH
Price
$3.05
$13.50
Analyst Decision
Hold
Strong Buy
Analyst Count
2
5
Target Price
$1.75
$18.50
AVG Volume (30 Days)
3.9M
720.1K
Earning Date
05-18-2026
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.88
Revenue
N/A
$15,386,000.00
Revenue This Year
$338.71
$70.90
Revenue Next Year
$24.16
N/A
P/E Ratio
N/A
$15.47
Revenue Growth
N/A
N/A
52 Week Low
$0.60
$7.90
52 Week High
$6.35
$21.03

Technical Indicators

Market Signals
Indicator
NRGV
TBPH
Relative Strength Index (RSI) 37.02 22.15
Support Level $2.86 $10.62
Resistance Level $3.54 $14.76
Average True Range (ATR) 0.24 0.92
MACD 0.05 -0.68
Stochastic Oscillator 26.81 5.60

Price Performance

Historical Comparison
NRGV
TBPH

About NRGV Energy Vault Holdings Inc.

Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: